{"id":"NCT03197935","sponsor":"Hoffmann-La Roche","briefTitle":"A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer","officialTitle":"A Phase III Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Neoadjuvant Anthracycline/Nab-Paclitaxel-Based Chemotherapy Compared With Placebo and Chemotherapy in Patients With Primary Invasive Triple-Negative Breast Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-07-24","primaryCompletion":"2020-04-03","completion":"2022-09-28","firstPosted":"2017-06-23","resultsPosted":"2021-06-02","lastUpdate":"2023-10-26"},"enrollment":333,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Triple-negative Breast Cancer"],"interventions":[{"type":"DRUG","name":"Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Nab-paclitaxel","otherNames":[]},{"type":"DRUG","name":"Doxorubicin","otherNames":[]},{"type":"DRUG","name":"Cyclophosphamide","otherNames":[]},{"type":"DRUG","name":"Filgrastim","otherNames":[]},{"type":"DRUG","name":"Pegfilgrastim","otherNames":[]}],"arms":[{"label":"Atezolizumab and Chemotherapy","type":"EXPERIMENTAL"},{"label":"Placebo and Chemotherapy","type":"PLACEBO_COMPARATOR"}],"summary":"This is a global Phase III, double-blind, randomized, placebo-controlled study designed to evaluate the efficacy and safety of neoadjuvant treatment with atezolizumab (anti-programmed death-ligand 1 \\[anti-PD-L1\\] antibody) and nab-paclitaxel followed by doxorubicin and cyclophosphamide (nab-pac-AC), or placebo and nab-pac-AC in participants eligible for surgery with initial clinically assessed triple-negative breast cancer (TNBC).","primaryOutcome":{"measure":"Number of Participants With Pathologic Complete Response (pCR) Using American Joint Committee on Cancer (AJCC) Staging System in ITT Population","timeFrame":"After neoadjuvant study treatment and surgery, up to primary analysis data cut off on 03 ApriI 2020","effectByArm":[{"arm":"Placebo and Chemotherapy","deltaMin":69,"sd":null},{"arm":"Atezolizumab and Chemotherapy","deltaMin":95,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0044"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":12,"exclusionCount":30},"locations":{"siteCount":68,"countries":["United States","Australia","Belgium","Brazil","Canada","Germany","Italy","Japan","Poland","South Korea","Spain","Taiwan","United Kingdom"]},"refs":{"pmids":["40467898","32966830","32450725"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":36,"n":167},"commonTop":["Alopecia","Nausea","Diarrhoea","Fatigue","Anaemia"]}}